

Supplemental Table for:
Real-World Clinical Outcomes in Locally Advanced or Metastatic Merkel Cell Carcinoma Patients in the United States: Results From SPEAR-Merkel
Abhijeet Bhanegaonkar et al.

Supplementary Table: Immunosuppressive medications within 28 days prior to the initiation of 1L treatment or during follow-up

Immunosuppressive Medications		
abatacept	dexamethasone >1 mg per day	mycophenylate
abatacept-maltose	eculizumab	natalizumab
adalimumab	etanercept	ofatumumab
alemtuzumab	everolimus	penicillamine
anakinra	FK506, tacrolimus	pentostatin
ATG (anti thymocyte globulin)	fludarabine	prednisolone >10 mg per day
azathioprine	golimumab	prednisone >10 mg per day
basiliximab	hydrocortisone >40mg per day	rituximab
belatacept	hydroxychloroquine	secukinumab (anti-IL17A)
belimumab	infliximab	sirolimus
betamethasone >1 mg per day	melphalan	sulfasalazine
certolizumab	mercaptopurine	temsirolimus
certolizumab pegol	methotrexate	thalidomide
chlorambucil	methylprednisolone >8 mg per day	tocilizumab (anti-IL6 receptor)
cladribine	muromonab-CD3 (Orthoclone OKT3)	tofacitinib (oral; jak 1 and jak 3 inhibitor)

cyclophosphamide	mycophenolate mofetil (MMF, CellCept)	triamcinolone >8 mg per day
cyclosporine	mycophenolate sodium (Myfortic)	Vedolizumab
Daclizumab	mycophenolic acid	